.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Dow
Citi
Colorcon
Johnson and Johnson
Merck
Daiichi Sankyo
Fish and Richardson
Chubb
Healthtrust

Generated: July 24, 2017

DrugPatentWatch Database Preview

DEPAKOTE ER Drug Profile

« Back to Dashboard

What is the patent landscape for Depakote Er, and when can generic versions of Depakote Er launch?

Depakote Er is a drug marketed by Abbvie and is included in one NDA. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-seven patent family members in twenty-seven countries.

The generic ingredient in DEPAKOTE ER is divalproex sodium. There are seventeen drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.

Summary for Tradename: DEPAKOTE ER

Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: see list10
Bulk Api Vendors: see list34
Clinical Trials: see list81
Patent Applications: see list2,885
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DEPAKOTE ER at DailyMed

Pharmacology for Tradename: DEPAKOTE ER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
DEPAKOTE ER
divalproex sodium
TABLET, EXTENDED RELEASE;ORAL021168-002May 31, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
Abbvie
DEPAKOTE ER
divalproex sodium
TABLET, EXTENDED RELEASE;ORAL021168-001Aug 4, 2000ABRXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie
DEPAKOTE ER
divalproex sodium
TABLET, EXTENDED RELEASE;ORAL021168-002May 31, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
Abbvie
DEPAKOTE ER
divalproex sodium
TABLET, EXTENDED RELEASE;ORAL021168-001Aug 4, 2000ABRXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie
DEPAKOTE ER
divalproex sodium
TABLET, EXTENDED RELEASE;ORAL021168-002May 31, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: DEPAKOTE ER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
DEPAKOTE ER
divalproex sodium
TABLET, EXTENDED RELEASE;ORAL021168-001Aug 4, 2000► Subscribe► Subscribe
Abbvie
DEPAKOTE ER
divalproex sodium
TABLET, EXTENDED RELEASE;ORAL021168-002May 31, 2002► Subscribe► Subscribe
Abbvie
DEPAKOTE ER
divalproex sodium
TABLET, EXTENDED RELEASE;ORAL021168-001Aug 4, 2000► Subscribe► Subscribe
Abbvie
DEPAKOTE ER
divalproex sodium
TABLET, EXTENDED RELEASE;ORAL021168-002May 31, 2002► Subscribe► Subscribe
Abbvie
DEPAKOTE ER
divalproex sodium
TABLET, EXTENDED RELEASE;ORAL021168-001Aug 4, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: DEPAKOTE ER

Drugname Dosage Strength RLD Submissiondate
divalproex sodiumExtended-release Tablets500 mgDepakote ER2/8/2005
divalproex sodiumExtended-release Tablets250 mgDepakote ER5/3/2004

International Patent Family for Tradename: DEPAKOTE ER

Country Document Number Estimated Expiration
Germany69913197► Subscribe
Portugal1216704► Subscribe
Australia2002239260► Subscribe
South Africa200104143► Subscribe
Hungary0105463► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Covington
QuintilesIMS
Cipla
Citi
Cerilliant
Mallinckrodt
Novartis
UBS
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot